Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Drug R&D

AACR 2023 Highlights: CAR-T Therapies and Monoclonal Antibody Combinations in Cancer Research

Fineline Cube Apr 21, 2023

The 2023 edition of the American Association for Cancer Research (AACR) annual meeting has concluded,...

Company Deals

Hasten Biopharmaceutical Secures $315 Million Investment for Pipeline Expansion

Fineline Cube Apr 21, 2023

China-based Hasten Biopharmaceutical Co., Ltd has reportedly received USD 315 million in a fundraising round...

Company Deals

Staidson Pharmaceutical Plans RMB 580 Million Private Placement for Drug R&D

Fineline Cube Apr 21, 2023

China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced plans to raise RMB 580...

Company Deals

Sangon Biotech Secures RMB 2 Billion in First Financing Round to Boost Life Science Services

Fineline Cube Apr 21, 2023

China-based contract research organization (CRO) Sangon Biotech has secured RMB 2 billion (USD 290.3 million)...

Company Deals

Shenzhen 01 Life Science Secures RMB 100 Million in Series B1 Financing for Microecology Platform

Fineline Cube Apr 21, 2023

Shenzhen 01 Life Science and Technology Ltd. Co., Ltd, a company specializing in human big...

Company Drug

Pfizer’s Prevenar 13 Receives Expanded Age Range Approval in China

Fineline Cube Apr 21, 2023

U.S.-based pharmaceutical giant Pfizer (NYSE: PFE) has reported receiving an additional indication approval from the...

Company Drug

BeiGene’s Tislelizumab-Chemo Combo Excels in RATIONALE 305 Trial for Gastric Cancer

Fineline Cube Apr 21, 2023

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced that the...

Company Deals

Zylox-Tonbridge Medical Teams Up with Hicicare Science for Guide Wire Product Sales in China

Fineline Cube Apr 21, 2023

China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced...

Company Deals

Shanghai Ark Biopharmaceutical’s STAR Market IPO Filing Accepted, Aims to Raise $289.6 Million

Fineline Cube Apr 21, 2023

Shanghai Ark Biopharmaceutical Co., Ltd’s Initial Public Offering (IPO) filing to the Shanghai Stock Exchange’s...

Company Drug

Hunan Warrant Pharmaceutical Receives NMPA Approval for Generic Brivudine

Fineline Cube Apr 21, 2023

Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving marketing...

Company Drug

Junshi Biosciences’ Tuoyi Combo Shows Promise in Phase III Neotorch Study for NSCLC

Fineline Cube Apr 21, 2023

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has published the results of the Phase III...

Company Deals

Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine’s HIV Drugs

Fineline Cube Apr 21, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a...

Company Medical Device

Acotec Scientific’s Vericor-14 Microcatheter Receives NMPA Approval for Vascular Surgeries

Fineline Cube Apr 21, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National...

Company Drug

Janssen’s Spravato Approved by NMPA for Adult Depression and Suicidal Ideation Treatment

Fineline Cube Apr 21, 2023

Janssen’s Spravato (esketamine) has been granted approval by the National Medical Products Administration (NMPA) in...

Company Drug

Jiangxi Jemincare Group Secures Clinical Trial Approvals for Four Innovative Drugs

Fineline Cube Apr 21, 2023

Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced receiving clinical trial approvals for four...

Company Drug

CSPC Pharmaceutical Group Gets NMPA Approval for SYS6010 ADC Clinical Trial

Fineline Cube Apr 21, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial...

Company Deals Drug

Legend Biotech’s Carvykti Data Boosts Stock Price by 19.64% on Positive Phase III Results

Fineline Cube Apr 20, 2023

Shares of Legend Biotech (NASDAQ: LEGN) jumped an impressive 19.64% in a single day, attributed...

Company Medical Device

Acotec Scientific Holdings Receives NMPA Approval for Paclitaxel-Coated Balloon Dilation Catheter

Fineline Cube Apr 20, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National...

Company Drug

CARSgen Therapeutics’ CT041 Receives NMPA Approval for Post-Operative Pancreatic Cancer Therapy

Fineline Cube Apr 20, 2023

China-based chimeric antigen receptor (CAR)-T cell specialist, CARSgen Therapeutics Holdings Ltd (HKG: 2171), has announced...

Company Drug

Zelgen Biopharmaceuticals’ ZG2001 Receives NMPA Approval for Clinical Trials

Fineline Cube Apr 20, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Posts pagination

1 … 577 578 579 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.